US Patent

US7851470 — Composition and methods for modulating a kinase cascade

Method of Use · Assigned to Kinex Pharmaceuticals LLC · Expires 2029-02-02 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds and methods for modulating one or more components of a kinase cascade.

USPTO Abstract

The invention relates to compounds and methods for modulating one or more components of a kinase cascade.

Drugs covered by this patent

Klisyri (TIRBANIBULIN) · Almirall

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3015`	—	Klisyri

Patent Metadata

Patent number: US7851470
Jurisdiction: US
Classification: Method of Use
Expires: 2029-02-02
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Kinex Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.